Preservation of Haemostasis with Anti-thrombotic Serotonin Antagonism

Abstract

An enquiry into the lack of attention awarded to serotonin antagonism in the treatment of arterial thrombosis revealed that the mode of action of serotonin and its platelet receptor antagonists was an action upon thrombus growth, and not, as with other anti-platelet drugs upon the initiation of thrombosis. This lack of effect could explain why this approach has been considered not to be effective. However under conditions of arterial stenosis in which there is platelet activation by increased shear stress, and during the growth phase of arterial thrombi, serotonin 5HT 2A antagonism has been demonstrated to have great potentcy in dispersing thrombotic obstruction to blood fl ow. This mode of action, the lack of participation of serotonin in haemostasis, and the absence of serotonin in wounds accounts for the proven lack of effect of effect of pure specifi c 5HT 2A antagonists (i.e., not those with other actions) on operative bleeding and skin bleeding times. This lack of effect on haemostasis solves the dosing problem encountered with other anti-thrombotic drugs, with which drug concentration cannot be controlled with single fi xed doses, leading to the association between increased antithrombotic effi cacy and increased bleeding complications. Thus 5HT 2A antagonism appears to be the preferred approach, from the point of view of safety and lack of bleeding risk; this consideration applies particularly to thrombosis therapy in the context of traumatic accidents, surgical operations and invasive procedures such as angioplasty.

Initiation of Arterial Stenotic Thrombosis

“…The additional benefit of this approach is that, there being no serotonin in wounds, the prediction is that there will be no bleeding complications, as occurs with dual antiplatelet therapy [4]. There is at least one of these drugs that has shown no change in bleeding time in patients [12,21,22].…”

Hemorheological Properties of the 5-Ht2a-Antagonist of the 2-Methoxyphenyl-Imidazobenzimidazole Derivative of the Ru-31 Compound and Cyproheptadine, in Comparison With Penthoxyphylline

“…Известно, что активация серотониновых рецепторов 2 типа вызывает сужение краниальных сосудов, повышает проницаемость капилляров и изменяет агрегацию тромбоцитов. Считается, что блокаторы данного подтипа рецепторов способны оказывать влияние на церебральную микроциркуляцию [14], а также способны ингибировать агрегацию тромбоцитов и эритроцитов, тем самым оказывая положительное влияние на реологические свойства крови улучшая микроциркуляцию [15][16][17].…”